SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.362
-0.588 (-14.97%)
Nov 7, 2024, 3:28 PM EST - Market open
SAB Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 9.17 | 56.57 | 15.05 | 33.21 | 12.61 | 6.35 |
Cash & Short-Term Investments | 30.4 | 56.57 | 15.05 | 33.21 | 12.61 | 6.35 |
Cash Growth | 1153.39% | 275.93% | -54.69% | 163.33% | 98.71% | - |
Receivables | 0.1 | - | 5.56 | 8.01 | 20.57 | 2.82 |
Prepaid Expenses | 2.04 | 2.34 | 1.49 | 2.64 | 1.28 | 0.12 |
Restricted Cash | - | - | - | 6.34 | - | - |
Total Current Assets | 32.54 | 58.91 | 22.1 | 50.19 | 34.46 | 9.29 |
Property, Plant & Equipment | 20.75 | 24.68 | 28.34 | 30.95 | 22.08 | 8.71 |
Other Long-Term Assets | 0.25 | 0.35 | 0.47 | - | - | - |
Total Assets | 53.8 | 83.94 | 50.9 | 81.14 | 56.54 | 18 |
Accounts Payable | 1.3 | 0.95 | 3.68 | 4.46 | 7.38 | 2.17 |
Accrued Expenses | 6.88 | 6.69 | 9.83 | 11.91 | 1.28 | 0.5 |
Short-Term Debt | - | - | - | - | - | 1.36 |
Current Portion of Long-Term Debt | - | 1.05 | 0.77 | 1.8 | 0.54 | 0.03 |
Current Portion of Leases | 0.52 | 0.8 | 0.62 | 1.3 | 1.12 | 0.55 |
Current Unearned Revenue | 0.11 | 1.32 | - | 0.1 | 0.1 | - |
Other Current Liabilities | - | - | 0.09 | 6.89 | 0.64 | - |
Total Current Liabilities | 8.82 | 10.81 | 14.99 | 26.46 | 11.06 | 4.62 |
Long-Term Debt | - | - | 0.54 | - | 0.17 | 0.05 |
Long-Term Leases | 4 | 4.05 | 3.99 | 5.42 | 6.3 | 5.64 |
Other Long-Term Liabilities | 4.08 | 11.77 | 0.32 | 10.72 | - | - |
Total Liabilities | 16.89 | 26.64 | 19.85 | 42.59 | 17.53 | 10.31 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 155.14 | 152.86 | 84.45 | 67.67 | 50.99 | 29.79 |
Retained Earnings | -112.77 | -90.06 | -47.87 | -29.13 | -11.98 | -32.1 |
Treasury Stock | -5.52 | -5.52 | -5.52 | - | - | - |
Comprehensive Income & Other | 0.05 | 0.03 | - | - | - | - |
Total Common Equity | 36.9 | 57.3 | 31.06 | 38.55 | 39.01 | -2.31 |
Shareholders' Equity | 36.9 | 57.3 | 31.06 | 38.55 | 39.01 | 7.69 |
Total Liabilities & Equity | 53.8 | 83.94 | 50.9 | 81.14 | 56.54 | 18 |
Total Debt | 4.52 | 5.91 | 5.93 | 8.52 | 8.13 | 7.64 |
Net Cash (Debt) | 25.88 | 50.66 | 9.12 | 24.69 | 4.48 | -1.29 |
Net Cash Growth | - | 455.59% | -63.07% | 450.61% | - | - |
Net Cash Per Share | 3.00 | 9.17 | 2.09 | 9.03 | 1.66 | -0.37 |
Filing Date Shares Outstanding | 9.23 | 9.23 | 5.04 | 4.3 | 3.52 | 3.52 |
Total Common Shares Outstanding | 9.23 | 9.23 | 5.04 | 4.35 | 3.52 | 3.52 |
Working Capital | 23.72 | 48.09 | 7.1 | 23.74 | 23.39 | 4.67 |
Book Value Per Share | 4.00 | 6.21 | 6.16 | 8.86 | 11.08 | -0.66 |
Tangible Book Value | 36.9 | 57.3 | 31.06 | 38.55 | 39.01 | -2.31 |
Tangible Book Value Per Share | 4.00 | 6.21 | 6.16 | 8.86 | 11.08 | -0.66 |
Machinery | - | 11.99 | 11.57 | 8.87 | 6.33 | 2.31 |
Construction In Progress | - | - | 0.31 | 4.61 | 6.73 | 0.08 |
Leasehold Improvements | - | 9.3 | 9.3 | 5.7 | 0.19 | 0.03 |
Source: S&P Capital IQ. Standard template. Financial Sources.